1 in 31
hospital patients
CDC reports that on any given day about 1 in 31 U.S. hospital patients has at least one healthcare-associated infection.
BQ-Skin
A program for severe hospital-acquired skin infection risk.
BQ-Skin is Biomilq Labs' first internally developed therapeutic program. It is being advanced for hospital settings, with a prevention-oriented focus on severe skin infection risk, including infection associated with Staphylococcus aureus.
Hospital settingsHospital-acquired infectionStaphylococcus aureus relevance
Scientific Context
Why the infection burden matters.
The development case for BQ-Skin starts with the burden of healthcare-associated infection in hospital settings. This is a clinical problem with both patient-risk and system-cost consequences.
687,000
estimated infections
CDC estimated 687,000 healthcare-associated infections in U.S. acute-care hospitals in 2015, with about 72,000 in-hospital deaths.
$28.4B-$45B
annual direct hospital cost
CDC estimated the direct annual medical cost of healthcare-associated infections to U.S. hospitals at $28.4 billion to $45 billion.
Unmet Need
Why new antimicrobial substances still matter.
A scientifically credible BQ-Skin page should explain not only the burden of hospital-acquired infection, but also the continuing need for new antimicrobial development in clinically important pathogen settings.
Hospital staph remains clinically important
CDC's 2019 Antibiotic Resistance Threats report estimated 323,700 MRSA cases in hospitalized patients and 10,600 deaths in 2017.
Resistant infections remain costly to manage
CDC reports that six of the most alarming antimicrobial-resistance threats contribute more than $4.6 billion in annual healthcare costs.
The antibacterial pipeline is still limited
WHO reported in June 2022 that only 27 antibiotics were in clinical development against priority pathogens, and only 6 met at least one innovation criterion.
Program Focus
How BQ-Skin is being framed publicly.
Hospital and acute-care focus
BQ-Skin is being developed for hospital and acute-care settings.
Prevention-oriented development case
The program is being framed around prevention of severe hospital-acquired skin infection risk, including infection associated with Staphylococcus aureus.
New antimicrobial need
The scientific case for BQ-Skin sits inside a broader unmet need for new antimicrobial substances that can address serious infection risk in clinical settings.
Development Inquiry
Start a scientific or development conversation on BQ-Skin.
This inquiry flow is for scientific, clinical, and strategic conversations tied specifically to the BQ-Skin development program.
Best for
- Clinical teams. Hospital, wound-care, acute-care, or infection-control conversations.
- Scientific collaborators. Preclinical, translational, or clinical-development discussions tied to the BQ-Skin program.
- Strategic capital. Investors or partners evaluating the BQ-Skin program in the context of the wider Biomilq Labs pipeline.
Inquiry Form